Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC) of the bladder in phase I trials. We conducted a phase II trial of this drug in patients with TCC of the bladder who failed a first line chemotherapy regimen.

Methods: Oral PTX was started at the dose of 25 mg three times per day for 5 days weekly for 3 weeks followed by one week of rest. If this was tolerated the dose was increased to 50 mg three times a day. Patients were monitored for response rate and toxicity.

Results: Seventeen patients were entered into the trial. Two patients did not complete the required 2 courses of treatment to be evaluable. There were 13 evaluable patients. Among the 13 no one achieved a complete response (CR), however, there were 3 partial responses (PRs=RR: 23%) and 5 stable diseases (SDs). The responses lasted 2, 8 and 14 months. The major dose limiting toxicity was myelosuppression. Two patients died on treatment. One death was due to neutropenic fever and the cause of death in the second patient is thought to be a cerebral vascular accident (CVA).

Conclusion: PTX is an active drug in the treatment of TCC of the bladder. Bone marrow suppression is the most common dose limiting toxicity. In view of the observed responses and toxicities in this study and other studies, we suggest that the role of PTX be further investigated in the following clinical settings:

1. Palliative initial treatment in patients with TCC of bladder who are not candidates for more aggressive chemotherapy.

2. As first line chemotherapy in combination with other active drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA 45:8–30, 1995

    Google Scholar 

  2. Loehrer PJ, Einhorn LH, Elson LH, Crawford PJ, Kuebler ED, Tannock P, Raghavan I, Stuart-Harris DA, Sarosdy R, Lowe MF, Blumenstein BA, Trump D: Randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066, 1992

    Google Scholar 

  3. Roth BJ, Bajorin DF: Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin. World J Urol 153:894–900, 1995

    Google Scholar 

  4. Fischer GA: Defective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178y leukemia cells. Biochem Pharmacol 11:1233–1234, 1962

    Google Scholar 

  5. Flintoff WF, Davidson SV, Siminovitch L: Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somatic Cell Gen 2:245–262, 1976

    Google Scholar 

  6. Galivan J: Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res 39:735–743, 1979

    Google Scholar 

  7. Niethammer D, Jackson RC: Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11:845–854, 1975

    Google Scholar 

  8. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ: Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 41:4447–4452, 1981

    Google Scholar 

  9. Albrecht AM, Biedier JL and Hitchinson DJ: Two different species of dihydrofolate reductase in mammalian cells differentially resistant to anwthoptetin and methasquin. Cancer Res 32:1539–1546, 1972

    Google Scholar 

  10. Alt FW, Kellems RE, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370, 1978

    Google Scholar 

  11. Hakala MT, Zakrzewski SF, Nichol CA: Relation of folic reductase to amethopterin resistance in cultured mammalian cells. J Biol Chem 236:952–958, 1961

    Google Scholar 

  12. Littlefield J: Hybridization of hamster cells with high and low folate reductase activity. Proc Natl Acad Sci USA 62:88–95, 1969

    Google Scholar 

  13. Rosowsky A, Mota CE, Queener SF, Waltham M, Ercikan-Abali E, Bertino JR: 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a sitedirected mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem 38(5):745–52, 1995

    Google Scholar 

  14. Flintoff WF, Essani K: Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 19:4321–4327, 1980

    Google Scholar 

  15. Jackson RC, Hart LI, Harrap KR: Intrinsic resistance to methotrexate of cultured mamrnalian cells in relation to the inhibition kinetics of their dihydrofolate reductase. Cancer Res 36:1991–1997, 1976

    Google Scholar 

  16. Lewis WS, Cody V, Galisky N, Luft JY, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakely RL: Methotrexate resistant variants of human dihydrofolate reductase with substitution of leucine 22. J Biol Chem 270(10):5057–5064, 1995

    Google Scholar 

  17. Chen G, Wright JE, Rosowsky A: Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates. Mol Pharmacol 48(4):758–765, 1995

    Google Scholar 

  18. Rosenblatt DS, Whitehead VM: Methotrexate polyglutamates in cultured human cells. Adv Exp Med Biol 163:275–285, 1983

    Google Scholar 

  19. Duch DS, Edelstein MP, Bowers SW, Nichols CA: Biochemical and chemotherapeutic studies in 2,4-diamino6 (1,5-dimethoxybenzyl)-5-methyl pyfido (2,3d) pyrimidine (BW 301u). A novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 42:3987–3994, 1982

    Google Scholar 

  20. Sigel CW, Macklin AW, Woolley JL, Johnson NW, Collier MA, Blum MR, Clendeninn NJ, Everm BIM, Grebe G, Mackars A, Foss R, Duch DS, Bowers SW, Nichol CA: Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophile inhibitor of dihydrofolate reductase. NCI Monogr 5:111–120, 1987

    Google Scholar 

  21. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MHN: Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res 45:978–982, 1985

    Google Scholar 

  22. Feun LG, Gonzales R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ: Phase II trial of piritrexim in metastatic melanoma using a intermittent, low dose administration. J Clin Oncol 9:464–467, 1991

    Google Scholar 

  23. Vokes EE, Dimery IW, Jacobs CD, Karp D, Molina A, Collier MA, Eble ML, Clendeninn NJ: A phase I study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. Cancer 67:2253–2257, 1991

    Google Scholar 

  24. Schiesel JD, Carabasi M, Magill G, Casper E, Cheng E, Marks L, Feyzi J, Clendeninn NJ, Smalley R: Oral piritrexim-A phase II study in patients with advanced soft tissue sarcoma. Inv New Drugs 10:97–98, 1992

    Google Scholar 

  25. de Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J: Oral piritrexim, an effective treatment for metastatic urothelial cancer. Brit J Cancer 67:388–390, 1993

    Google Scholar 

  26. de Vries EG, Gietema JA, Workman P, Scott JE, Crawshaw A, Dobbs HT, Dennis, Mulder N, Sleijfer D, Willemse PH: A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. Brit J Cancer 68(3):641–644, 1993

    Google Scholar 

  27. Bleehen NM, Newman HV, Rampling RP, Ramsay JR, Roberts JT, Bedford P, Nethersell AB: A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma. Brit J Cancer 72(3):766–768, 1995

    Google Scholar 

  28. Feun LG, Savaraj N, Bandito P, Waldman S, Collier M, Glendennin N: Oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy? Am J Clin Oncol 17(15):448–451, 1994

    Google Scholar 

  29. Feun LG, Savaraj N, Benedetro P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ: Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst 83:51–55, 1991a

    Google Scholar 

  30. Laszlo J, Brenckman WD, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C: Initial clinical studies of piritrexim NCI Monogr 5:121–125, 1987

    Google Scholar 

  31. Yagoda A: Chemotherapy of the urothelial tract tumors. Cancer 60:574, 1987

    Google Scholar 

  32. Troner M, Birch R, Omura GA, Williams S: Phase III comparison of cisplatin versus cisplatin doxorubicin and cyclophosphamide in the treatment of bladder (U Jrothelia) cancer: a Southeastern Cancer Study Group trial. J Urol 37(4):660–662, 1987

    Google Scholar 

  33. Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr, Coombs J: A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. Cancer 1,52(5):767–772, 1983

    Google Scholar 

  34. Hillcoat BL, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R, Olver I, Bishop J, Pearson B, Coorey G: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7(6):706–709, 1989

    Google Scholar 

  35. Khandekar JD, Elson PJ, DeWys WD, Slayton RE, Harris DT: Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin cyclophosphamide and DDP in disseminated transitional cell carcinomas of the urinary tract. J Clin Oncol 3(4):539–545, 1985

    Google Scholar 

  36. Roth BJ, Dreicer R, Einhorn LH, et al.: Significant activity of Paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol 12:2264–2270, 1994

    Google Scholar 

  37. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabinc in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5(2):182–184, 1994

    Google Scholar 

  38. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12(11):2271–2276, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Wisconsin, Madison, WI, 53792

    Masoud Khorsand, Joan Lange & George Wilding

  2. University of Miami, Miami, FL

    Lynn Feun

  3. Agouron Pharmaceuticals, USA

    Neil J. Clendeninn & Mary Collier

Authors
  1. Masoud Khorsand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn Feun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil J. Clendeninn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary Collier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George Wilding
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khorsand, M., Lange, J., Feun, L. et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 15, 157–163 (1997). https://doi.org/10.1023/A:1005860806635

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005860806635

Search

Navigation